SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that data from the Company’s Phase 1 multiple ascending dose study of GB004 in healthy volunteers have been accepted for presentation at the 2020 Crohn’s & Colitis Congress being held January 23- 25 in Austin, Texas.
Details for the presentation are as follows:
Session Type: Poster Session Session Title: Controlled Clinical Trials in Humans Session Date and Time: Thursday, January 23, 2020; 7:00- 9:00 p.m. CT Presentation Number: P066 Presentation Title: GB004, A Novel Gut-Targeted Prolyl Hydroxylase Inhibitor for Inflammatory Bowel Disease: First-In-Human, Multiple-Dose Study in Healthy Subjects With Gut Biopsies Presenter Name: Barrett Levesque, MD Location: Exhibit Hall 01 – Austin Convention Center
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200123005225/en/
For Investors: Argot Partners Tel 212.600.1902 gossamerbio@argotpartners.com
For Media: Argot Partners David Rosen Tel 212.600.1902 david.rosen@argotpartners.com
Source: Gossamer Bio, Inc.